Delayed Treatment with the Novel HSP90 inhibitor TAS-116 Ameliorate Hydrochloric Acid-Induced Pulmonary Fibrosis
P. Solopov (Norfolk, United States), R. Colunga Biancatelli (Norfolk, United States), C. Dimitropolou (Norfolk, United States), T. Day (Norfolk, United States), J. Catravas (Norfolk, United States)
Source: International Congress 2022 – Identifying therapeutic targets and novel drug strategies in pulmonary diseases
Rating: 
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
P. Solopov (Norfolk, United States), R. Colunga Biancatelli (Norfolk, United States), C. Dimitropolou (Norfolk, United States), T. Day (Norfolk, United States), J. Catravas (Norfolk, United States). Delayed Treatment with the Novel HSP90 inhibitor TAS-116 Ameliorate Hydrochloric Acid-Induced Pulmonary Fibrosis. 2835
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
|
|